Tag: Patient safety

US trade enforcement action likely against India, pharma companies to be hit

The U.S. trade representative on Monday will announce a trade enforcement action tied to India, his office said, a move that could further rile relations after an incident last year involving the arrest and strip-search of an Indian consul. U.S. Trade Representative Michael Froman will discuss the action at a news conference at 2 p.m…. Read More ›

Goan pharma industry wants finance commission to focus on state’s export potential while dolling out tax incentives

With a view to provide better growth opportunity for the pharma sector in Goa, the industry wants the chairman and members of finance commission to work out a mechanism that will focus on giving due weight-age to the export while dolling out tax incentives. Industry feels that by doing this, the states share from the… Read More ›

FDI in pharma jumps to $1.25 billion during April -November period

NEW DELHI: Foreign direct investment in the pharma sector has more than doubled to $1.25 billion during April-November period of the fiscal even amid concerns about the spate of acquisitions of domestic firms by MNCs. FDI in drugs and pharmaceuticals was $581 million during April-November 2012, according to the latest data of the Department of… Read More ›

How Bioelectronics Will Cure Cancer

When you think of cyborgs becoming a reality, you probably picture Arnold Schwarzenegger’s glowing red eye from Terminator or the steely, tight-lipped stare of Robocop. But the future where man and machine converge won’t just be built with nuts and bolts. It will be built with biology. Self-avowed cyborg expert Tim Maly said as much when I talked… Read More ›

If I follow US standards, I will have to shut almost all drug facilities: G N Singh

 At a time India-made medicines appear to be losing sheen the world over, the country’s top regulator, the Drug Controller General of India (DCGI), is struggling to ensure quality of drugs in the domestic market. Faced with criticism on many fronts, DCGI feels the India market might not be ready to follow global standards and the Indian… Read More ›

Expert speak: How Indian pharma companies can grow their business

In the past few years, the Indian pharmaceutical Industry (IPI) has grown at nearly 12 to 15 per cent which is a tremendous pace of growth if we compare it to that of the US or European markets. No doubt the growth of the industry will continue to be in double digits and India may rank… Read More ›

Pharma, healthcare sectors are the Fulcrum of its investments

Having morphed from a proprietary fund into one that invests in early-stage ventures, Fulcrum Ventures will continue with its focus on the pharmaceutical and wellness space. That is because of historical reasons, explains Krishna Ramanathan, Founder-Partner, Fulcrum. Fulcrum was set up with the money that Krishna’s father gave him, from the proceeds that he got… Read More ›

Indian pharma’s twin woes

The Indian pharmaceutical industry is beset by two adverse conditions – one is a recent development and the other a long-standing malady. Most recently, leading pharmaceutical company Ranbaxy met with yet another regulatory mishap: the United States Food and Drug Administration, or FDA, withdrew approval for the firm’s Toansa plant because of significant lapses in manufacturing practices. The fourth Indian… Read More ›

Are Indian pharma companies overdosing on lethal drug of fraud?

We now know that the behaviour that led Ranbaxy to sign the “unprecedented” consent decree in 2012 with the US Food & Drug Administration (FDA) was not limited to just two manufacturing sites. In 2013, the US regulator brought its Mohali facility and last week its Toansa API facility under the consent decree. Clearly, public… Read More ›

Pharma Spectrum 2014 to be held in Mumbai on Feb 20

Goldman Communications & Infinity Business Services will be holding Pharma Spectrum 2014, a must attend conference for companies and solution providers of pharma industry, at The Holiday Inn, Mumbai on February 20. This business initiative will be having three distinct and innovative parallel tracks on pharma manufacturing excellence, innovations in drug delivery system (DDS) and… Read More ›